Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Current pharmaceutical design

Showing results (21-30 of 10,647) with videos related to

Pageof 1,065
Sort By:
Current Pharmaceutical Design|December 7, 2010
Sealing the envelope - the HIV-1 envelope glycoproteins as targets for therapeutics and vaccinesRogier W Sanders, Ben Berkhout
Current Pharmaceutical Design|December 7, 2010
Therapeutic antibodies in HIV treatment--classical approaches to novel advancesIrene A Abela, Lucy Reynell, Alexandra Trkola
Current Pharmaceutical Design|December 7, 2010
Chronic hepatitis C, insulin resistance and vascular diseaseAndreja Trpkovic, Edith Stokic, Djordje Radak, et al.
Current Pharmaceutical Design|December 7, 2010
Herbal medicines and nutraceuticals for diabetic vascular complications: mechanisms of action and bioactive phytochemicalsEshaifol A Omar, Antony Kam, Ali Alqahtani, et al.
Current Pharmaceutical Design|December 7, 2010
Targeting IL-23 and Th17-cytokines in inflammatory bowel diseasesDaniela De Nitto, Massimiliano Sarra, Maria Laura Cupi, et al.
Current Pharmaceutical Design|December 7, 2010
Current developments for the diagnosis and treatment of irritable bowel syndromeOliver Grundmann, Saunjoo L Yoon, Baharak Moshiree
Current Pharmaceutical Design|February 24, 2011
Self assembling polymers as polymersomes for drug deliveryJay Prakash Jain, Wubeante Yenet Ayen, Neeraj Kumar
Current Pharmaceutical Design|February 26, 2011
Matter of life and death: the pharmacological approaches targeting apoptosis in brain diseasesVirve Cavallucci, Marcello D'Amelio
Current Pharmaceutical Design|February 26, 2011
Promotion of apoptosis in cancer cells by selective purine-derived pharmacological CDK inhibitors: one outcome, many mechanismsJózefa Węsierska-Gądek, Margarita Maurer
Current Pharmaceutical Design|March 3, 2011
Steroid 5α-reductase as a novel therapeutic target for schizophrenia and other neuropsychiatric disordersSilvia Paba, Roberto Frau, Sean C Godar, et al.
Pageof 1,065

Showing results (21-30 of 10,647) with videos related to

Sort By:
Pageof 1,065
Current Pharmaceutical Design|December 7, 2010
Sealing the envelope - the HIV-1 envelope glycoproteins as targets for therapeutics and vaccinesRogier W Sanders, Ben Berkhout
Current Pharmaceutical Design|December 7, 2010
Therapeutic antibodies in HIV treatment--classical approaches to novel advancesIrene A Abela, Lucy Reynell, Alexandra Trkola
Current Pharmaceutical Design|December 7, 2010
Chronic hepatitis C, insulin resistance and vascular diseaseAndreja Trpkovic, Edith Stokic, Djordje Radak, et al.
Current Pharmaceutical Design|December 7, 2010
Herbal medicines and nutraceuticals for diabetic vascular complications: mechanisms of action and bioactive phytochemicalsEshaifol A Omar, Antony Kam, Ali Alqahtani, et al.
Current Pharmaceutical Design|December 7, 2010
Targeting IL-23 and Th17-cytokines in inflammatory bowel diseasesDaniela De Nitto, Massimiliano Sarra, Maria Laura Cupi, et al.
Current Pharmaceutical Design|December 7, 2010
Current developments for the diagnosis and treatment of irritable bowel syndromeOliver Grundmann, Saunjoo L Yoon, Baharak Moshiree
Current Pharmaceutical Design|February 24, 2011
Self assembling polymers as polymersomes for drug deliveryJay Prakash Jain, Wubeante Yenet Ayen, Neeraj Kumar
Current Pharmaceutical Design|February 26, 2011
Matter of life and death: the pharmacological approaches targeting apoptosis in brain diseasesVirve Cavallucci, Marcello D'Amelio
Current Pharmaceutical Design|February 26, 2011
Promotion of apoptosis in cancer cells by selective purine-derived pharmacological CDK inhibitors: one outcome, many mechanismsJózefa Węsierska-Gądek, Margarita Maurer
Current Pharmaceutical Design|March 3, 2011
Steroid 5α-reductase as a novel therapeutic target for schizophrenia and other neuropsychiatric disordersSilvia Paba, Roberto Frau, Sean C Godar, et al.
Pageof 1,065